



RE: Annual Shareholder Letter

Dear CVR Medical Corporation Shareholder,

As an introduction to 2018, I would like to review the progress we've made this past year, as well as lay out the roadmap for the upcoming one. First and foremost, I would like to take the opportunity to celebrate the momentous progress in our effort to bring the Carotid Stenotic Scan (CSS) to the healthcare industry. Upon completion of two phases of tertiary clinical trials at Thomas Jefferson University Hospital, we have collected data which has been invaluable to move the device forward from both efficacy validation and human factor perspectives. This progress resulted in a clinical report that was disseminated mid-year at a cost which was millions of dollars less than previously anticipated, all while keeping close to our original timeline. In addition, significant progress was made on the operational side in 2017, specifically with the announcement of a signed LOI with Canon Virginia (CVI) to handle manufacturing, logistical, and customer service needs. This, combined with the completion and implementation of the long awaited wireless CSS device into clinical trials, the ongoing negotiations for distribution rights between various countries, and continued creation of all documentation necessary for an intended Q1 2018 FDA submission, go to substantiate the banner year. Internal to CVR Medical, the momentum continued with the addition of various key personnel and the announcement of the LOI to transform the 50/50 Joint Venture to a 60 /40 Joint Venture, where CVR Medical shareholders stand to realize an additional 10% ownership stake in all Carotid focused technologies. Though much of this is repetition to you, I strongly believe that to understand where we are going we must also understand how far we have come.

Now, we shift our focus to the future, specifically 2018. With pivotal trials planned for launch early January to acquire the clinical substantiation for FDA submission scheduled for late Q1, 2018 promises the realization of almost a decade of hard work. As these key milestones are met, we will shift our focus to laying the

foundation for a fast, seamless, and effective market introduction and release. Through the pending finalization of our shift to 60% control of our Joint Venture, our collaboration with Canon, the launch of clinical trials at industry leading research institutions, the continued negotiations for exclusive distribution rights globally, and the selection of distribution partners, the near and long-term potential of CVR is unceasing.

Now, I would like to touch on several topics which come up frequently in my conversations with all. Primarily news flow and corporate transparency. Unlike many industries where information can be communicated almost real-time, the publicly traded medical device sector is governed by a wide range of regulatory bodies, all of which are looking out to protect their stakeholders. Whether prosecuting patents with the Patent & Trademark Office, protecting future patients through FDA compliance, or making continuous disclosure with securities regulators, CVR is required to commit a significant amount of time and resources to the dissemination of information. It is always the intention of our entire management team and board to ensure we are standing on a strong footing of accuracy and legality in any and all situations. This commitment can oftentimes hamper speed of information to the market to ensure regulatory compliance. I assure you that as we meet our milestones, advance the project, and endeavor to increase shareholder value, we will do everything possible to afford you, the investor, the transparency possible within all regulatory environments.

In closing, our team has worked hard to deliver our stated milestones, and we are all be proud and thankful of the accomplishments. To our shareholders, on behalf of the entire CVR team and board, we are grateful for the continued support, appreciative of the opportunity, respectful of the challenge, and committed to deliver on the outcome. Please feel free to contact me directly with any questions.

Sincerely,

A handwritten signature in black ink, appearing to read 'Peter Bakema', with a long horizontal flourish extending to the right.

Peter Bakema
Chairman / Chief Executive Officer
CVR Medical Inc.

This press release contains forward-looking information that involves various risks and uncertainties regarding future events related to the our proposed joint-venture transactions, clinical trials, FDA submissions, and other business. Such statements are subject to risks and uncertainties that may cause actual results, performance or developments to differ materially from those contained in the statements and are not guarantees of future performance of the Company. No assurance can be given that any of the events anticipated by the forward-looking statements will occur or, if they do occur, what benefits the Company will obtain from them. These forward-looking statements reflect management's current views and are based on certain expectations, estimates and assumptions which may prove to be incorrect. A number of risks and uncertainties could cause our actual results to differ materially from those expressed or implied by the forward-looking statements, including: (1) a downturn in general economic conditions in North America and internationally, (2) the inherent uncertainties and speculative nature associated with commercialization of technology and the practice of medicine, (3) a change in health regulations, (4) any number of events or causes which may delay or cease commercialization and development of the Joint Venture, (5) the risk that the Company or the Joint Venture does not execute its business plan, (6) inability to retain key employees, (7) inability to finance operations and growth, and (8) other factors beyond the Company's control. These forward-looking statements are made as of the date of this news release and, except as required by law, the Company assumes no obligation to update these forward-looking statements, or to update the reasons why actual results differed from those projected in the forward-looking statements.

THE TSX VENTURE EXCHANGE INC. HAS NEITHER APPROVED NOR DISAPPROVED THE CONTENTS OF THIS PRESS RELEASE. NEITHER THE TSX VENTURE EXCHANGE NOR ITS REGULATION SERVICES PROVIDER (AS THAT TERM IS DEFINED IN THE POLICIES OF THE TSX VENTURE EXCHANGE) ACCEPTS RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.